

Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) (Musculoskeletal Disorders) - Drugs in Development, 2021

<https://marketpublishers.com/r/L17622A14A50EN.html>

Date: April 2021

Pages: 30

Price: US\$ 2,000.00 (Single User License)

ID: L17622A14A50EN

Abstracts

Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) (Musculoskeletal Disorders) - Drugs in Development, 2021

SUMMARY

Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) (Musculoskeletal Disorders) - Drugs in Development, 2021 provides an overview of the Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

NOTE:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the Global Therapeutic Landscape of Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) (Musculoskeletal Disorders).

The report reviews pipeline therapeutics for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The report covers pipeline products based on various stages of development ranging from discovery till pre-registration.

The report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive MoA, R&D Brief, Licensing and Collaboration details & Other Developmental Activities.

The report reviews key players involved in the development of Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The report assesses Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) (Musculoskeletal Disorders) therapeutics based on Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

The report summarizes all the dormant and discontinued pipeline projects.

The report reviews latest news related to pipeline therapeutics for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) (Musculoskeletal Disorders).

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective Research and Development (R&D) strategies.

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Identify and understand important and diverse types of therapeutics under development for Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) (Musculoskeletal Disorders).

Identify potential new clients or partners in the target demographic.

Develop strategic initiatives by understanding the focus areas of leading companies.

Plan Mergers and Acquisitions (M&A) effectively by identifying key players and it's most promising pipeline therapeutics.

Devise corrective measures for pipeline projects by understanding Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope.

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Indication - Overview
- Indication - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Indication - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Indication - Companies Involved in Therapeutics Development
- Company 1
- Company 2
- Company 3
- Company XX
- Indication - Drug Profiles
- Drug 1 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drug 2 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drug 3 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drug 4 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Drug XX - Drug Profile

Product Description
Mechanism of Action
R&D Progress
Indication - Dormant Projects
Indication - Discontinued Products
Indication - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Indication, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Indication - Pipeline by Company 1, 2021
Indication - Pipeline by Company 2, 2021
Indication - Pipeline by Company 3, 2021
Indication - Pipeline by Company XX, 2021
Indication - Dormant Projects, 2021
Indication - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Indication, 2021
- Number of Products under Development by Companies, 2021
- Number of Products under Development by Universities/Institutes, 2021
- Number of Products by Top 10 Targets, 2021
- Number of Products by Stage and Top 10 Targets, 2021
- Number of Products by Top 10 Mechanism of Actions, 2021
- Number of Products by Stage and Top 10 Mechanism of Actions, 2021
- Number of Products by Routes of Administration, 2021
- Number of Products by Stage and Routes of Administration, 2021
- Number of Products by Top 10 Molecule Types, 2021
- Number of Products by Stage and Top 10 Molecule Types, 2021

I would like to order

Product name: Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD or LAMA2-Related Muscular Dystrophy) (Musculoskeletal Disorders) - Drugs in Development, 2021

Product link: <https://marketpublishers.com/r/L17622A14A50EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L17622A14A50EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

